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Human prolactin receptor (PRLR) transcripts and their protein products exhibit heterogenic structures 
and functions. This multiplicity constitutes a gene regulatory system. Short PRLR might modulate 
longer PRLR structures and signaling. Here we overviewed 10 forms (including two putative forms) of 
PRLR structures, signaling and functions and analyzed the possible regulatory system regarding 
multiple PRLRs. Particularly, we discovered that a mimic of phosphorylated prolactin induced p21 waf1 
expression via a short form of PRLR S1b in prostate cancer cells. In addition, an intron retention was 
discovered in PRLR mRNA transcript via sequence analysis, showing that an intron encodes PRLR 
once needed. PRLR splicing and intron retention might be a critical modulating system to regulate 
PRLR structures and functions. Furthermore, PRLR genomic size was extended to 182 kb, versus the 
former report, 70 kb. Interestingly, dozens of PRLR-linked genes on chromosome 5 might interplay one 
another. This review fully uncovered the associations in PRLR multiplicity and functions, suggesting 
that shorter PRLR might modulate long PRLR function via multiple PRLR system in both mRNA and 
protein levels. 
 





Prolactin is a pituitary-secreted hormone, which functions 
via binding PRLR and further activates a series of signa-
ling pathways leading to necessary physiological actions 
in paracrine, autocrine and endocrine ways in vitro and in 
vivo (Ben-Jonathan et al., 2008; Goffin et al., 2005; 
Teilum et al., 2005). PRLR was cloned first in rodents 
(Davis and Linzer, 1989). A variety of rodent PRLR iso-
forms were characterized and a large amount of work 
was done focused on rat PRLR multiplicity (Ben-
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2005). However, little was highlighted on human PRLR 
multiplicity. Similar to the discovery of multiple growth 
hormone receptors, by using rodent PRLR cDNA probes, 
so far at least 10 isoforms (including two putative forms) 
of human PRLR have been characterized (Boutin et al., 
1989; Kline et al., 1999; Kline et al., 2002; Hu ZZ et al., 
2001; Trott et al., 2003; Fuh and Wells, 1995; Somers et 
al., 1994; Laud et al., 2000). These PRLR variants were 
defined as long form (LF), intermediate form (IF), S1 
and the other seven short forms on the basis of their 
molecular weights and structures. The short forms 
include S1a, S1b, 4- SF1b, 7/11, 4-7/11 and two 
putative soluble forms. Herein we defined them as 
soluble short forms (SS1 and SS2). In addition, a 32 kD 
PRL-binding protein (PRLBP) was identified in human 
serum and milk (Kline and Clevenger, 2001). However, 
some confusion in terms of PRLR definition in literature 
was made. Different forms of the PRLR have been 
designated based upon the length of their intracellular 
domains (Ormandy et al., 1998), but the S1and S1a are 
longer than the IF PRLR. In effect, because PRLR has 
multiple forms with a variety of sizes, it is difficult to 





noticed that the IF PRLR, S1a, S1b, 4- SF1b, 7/11, 
4-7/11, SS1 and SS2 are also mutant forms derived 
from frame shift. These differential PRLR isoforms origin-
nated from either the alternatively spliced transcripts or 
proteolysis, or both (Boutin et al., 1989; Kline et al., 1999; 
Kline et  al.,  2002; Hu ZZ  et  al., 2001; Trott  et  al., 2003; 
Fuh and Wells, 1995; Somers et al., 1994; Laud et al., 
2000). These PRLR transcripts come from multiple 5’ and 
3’-untranslated regions (UTR) and alternatively spliced 
exons and introns (Hu ZZ et al., 1999; Hu ZZ et al., 2002). 
By cotransfection with beta-casein promoter-luciferase 
construct into HEK293 cells, short forms of PRLR S1a 
and S1b were demonstrated to not induce beta-casein 
gene expression in response to prolactin (Hu ZZ et al., 
2001). Nevertheless, in rodent, some short form PRLR 
was demonstrated to modulate proliferation and diffe-
rentiation (Das and Vonderhaar, 1995; Qazi et al., 2006). 
In our opinion, the formation of short PRLR via premature 
stop codon might be a regulatory system to modulate the 
quantity of long PRLRs. Thus, short PRLR might regulate 
the signaling pathways of long PRLR. This also might 
result from PRLR heterodimization or the ligand com-
petition to protect cells from exposure to high levels of 
lactogen (Edens and Talamantes, 1998; Horseman, 
2002). Another possibility is that some short PRLRs work 
in a unique signaling pathway, such as the signaling via 
PRL associated protein (PRAP) (Duan et al., 1997). 
In reference to soluble growth hormone receptor, some 
soluble forms of PRLR were assumed to have the follow-
ing functions: 1) increase prolactin half-life by stabilizing 
prolactin structure (Baumann, 1993); and 2) serve as a 
storage reservoir for prolactin and growth hormone (GH) 
so that they can be released upon requirements 
(Kopchick and Andry, 2000). Human GH also binds to the 
extracellular domain of the hPRLR via 1:1 complex 
(Somers et al., 1994); 3) Serve as a transporter for 
circulating PRLR and growth hormone (Horseman, 2002). 
Similar to growth hormone binding protein (GHRBP), 
these soluble forms of PRLR come from proteolysis and 
PRLR mRNA alternative splicing (Boutin et al., 1989; 
Kline et al., 1999; Kline et al., 2002; Hu ZZ et al., 2001; 
Trott et al., 2003; Fuh and Wells, 1995; Somers et al., 
1994; Laud  et al., 2000) and 4) They compete ligands 
with long PRLR to antagonize the effect of the latter 
(Mannor  et al., 1991). 
In this review, we also elucidated the gene-gene inte-
raction on this chromosome 5. Evidences show that 
PRLR gene and many other genes on chromosome 5 
have some functional associations in the PRL signaling 
pathways. Some of them constituting the cytokine recep-
tor superfamily class 1 might originate from the same 
ancestor gene as a result of evolution (Bole-Feysot et al., 
1998). The advantage for those genes to localize on the 
same chromosome is to maintain the conservation and 
stability of these genes in genetics (Arden et al., 1990). It 
is not clear whether the localization is a convenient 
requirement for their mutual regulation. 




HUMAN PRLR GENE STRUCTURE  
 
The gene encoding human PRLR was localized on chro-
mosome 5p13-p14 (Bole-Feysot et al., 1998). The 
analysis of human chromosome 5 clone CTD-2046J7 
(accession No: AC010368) and human chromosome 5 
genomic contig (accession No: NT_006679) by NCBI 
Blast (http://www.ncbi.nlm.nih.gov/entrez) revealed that 
human PRLR gene exceeds 182 kb in length (Figure 1). 
This is the closest calculation in literature so far. Human 
PRLR gene contains a multiple promoter region (hPIII 
and hPN) and at least 11 exons (Hu et al., 1999, 2002; 
Das and Vonderhaar, 1995). The 5’-UTR of the human 
PRLR gene contains at least 6 alternative non-coding 
exon 1 (generic E13, E1N1, E1N2, E1N3, E1N4 and 
E1N5), a non-coding exon 2 and a non-coding part of 
exon 3 (Hu et al., 1999, 2002). The partial exon 3, exon 4, 
5, 6 and 7 encode the extracellular domain of human 
PRLR. The exon 8 encodes all transmembrane domains 
and exon 10 encodes most of the intracellular domains. 
The first exon E13 is a predominant form in most tissues 
(Hu et al., 1999, 2002). Promoter hPIII and hPN were 
demonstrated to use distinct mechanisms to regulate 
hPRLR transcription (Hu et al., 1999, 2002). S1a and S1b 
possess different putative poly A signal (AGTAAA) from 
that (AATAAA) in the long form of PRLR in 3’-UTR (Hu 
ZZ et al., 1999, 2002; Das and Vonderhaar, 1995).  
 
 
HUMAN PRLR TRANSCRIPT HETEROGENEITY 
 
Human multiple PRLR transcripts have been detected in 
a variety of tissues and cells (Boutin et al., 1989; Kline et 
al., 1999; Kline et al., 2002; Hu ZZ et al., 2001; Trott et al., 
2003; Fuh and Wells, 1995). Multiple forms of 5’-UTR 
and 3’-UTR of PRLR (including alternative polyadeny-
lation signal) were reported (Hu ZZ et al., 1999, 2002). 
Heterogeneity of human PRLR transcripts is generated 
by several types of alternative splicing, including alter-
native splicing within exons, intron retention, alternative 
transcription start and termination sites, deletion of partial 





In addition to multiple exon 1, multiple promoters and 
multiple transcription start sites were discovered in 
human PRLR genes (Hu ZZ et al., 1999, 2002). Moreover, 
in some disease tissues, PRLR single nucleotide poly-
morphisms (SNPs) in 5’-UTR region were reported (Lee 
et al., 2007). By analysis of human PAC library, two alter-
native promoters, a generic promoter hPIII common to 
human and rats and a human specific promoter hPN 
were cloned and characterized (Hu ZZ et al., 1999, 2002). 
These different promoters possess transcriptional factor 
Sp1 and C/EBP binding sites. Human GHR transcripts  






Figure 1. Prolactin receptor genomic (upper panel) and multiple transcript structures (lower panel). Filled 
boxes indicate exons, the spaces between exons represent introns. The size interval is not equivalent. PRLR 




have been demonstrated to have 8 alternative 5’-UTR, at 
least one of them is tissue-specific (Edens and 
Talamantes, 1998). In addition, in rodents, three tissue-
specific PRLR promoters, PI, PII and PIII were cloned; it 
is believed that the tissue-specific PRLR promoters were 
utilized in human. Multiple 5’-UTR might involve different 
levels of transcription and the expression of different 
transcripts in tissue-specific way. 
 
 
Deletions in coding region 
 
Several forms of PRLR transcripts were found with dele-
tion and in transmembrane and intracellular domain-
encoding regions, see Figure 1. The deletion resulted in 
the truncated and mutant PRLR proteins. These PRLRs 
might alter PRL signaling pathways and further lead to 
different biological properties of PRLR, such as prolife-
ration and differentiation (Das and Vonderhaar, 1995; 
Horseman, 2002). 
 
1. Extracellular domain (ECD)-encoding mRNA deletion: 
the receptor S1 mRNA was characterized in breast can-
cer T47D cells with a deletion of whole part of exon 4 and 
exon 5. Partial exon 3 encodes a 24 amino acid signal 
peptide (Kline et al., 2002). The SS2 mRNA was charac-
terized   by   a  deletion  of  exon  6  completely  (Hu et al.,  
1999). 
2. Transmembrane domain (TM)-encoding and intracellular- 
domain (ICD) encoding mRNA deletion: The receptor  
7/11 mRNA lacks transmembrane-encoding exon 8 and 
intracellular-domain encoding exon 9, 10, but it has a 
partial exon 11 (Trott et al., 2003). The receptor 4-7/11 
mRNA lacks both extracellular domain-enco-ding exon 3, 
4, and transmembrane domain-encoding exon 8, and 
intracellular-domain encoding exon 9, 10, but it has a 
partial exon 11 (Trott et al., 2003). It is not clear whether 
4-7/11 is a product of  7/11 proteolysis because the 
first amino acid for 4-7/11 is methionine. The IF PRLR 
mRNA was also discovered in T47D cells with exon 3 
and two incomplete parts of exon 10 (Kline et al., 1999). 
In other words, there is a deletion in exon 10. Also, a 
frame shift was found in protein encoding. The receptor 
S1a mRNA comprises exon 3 to exon 11 with a detetion 
of exon 10. A frame shift was made by alter-native 
splicing of partial exon 10 and exon 11 in the gene 
product (Hu et al., 2001; Trott et al., 2003). The receptor 
S1b mRNA contains exons from 3 to 9 plus partial exon 
11 with a deletion in the intracellular- domain encoding 
exon 10 and its coding region has a frame shift (Hu et al., 
2001; Trott et al., 2003). The receptor  4-SF1b mRNA 
contains all exons in S1b except exon 3 and 4. However, 
its product might not come from S1b proteolysis because 
the first amino acid is methionine. The SS1 mRNA contains  










exons 4, 5, 6, 7 and 9. Alternative splicing leads to a 
frame shift and a deletion of total transmembrane domain 
and ICD. The SS2 mRNA has a deletion of exon 6 in 
extracellular domain. The deletion might induce a frame 
shift and a premature termination codon in the extra-





By sequence comparision, we made a discovery that long 
form of PRLR mRNA owns a 3’-UTR which comes from 
partial intron 10/11. Intron retention was reported in 
growth hormone receptor (Edens and Talamantes, 1998). 
Therefore, whether the long form of PRLR is the longest 
one is still a question. The 3’-UTR for LF PRLR has an 
AATAA poly A signal. However, the mRNA with exon 11 
encoding S1a, S1b, 7/11, 4-7/11, and 4-SF1b has 
distinct 3’-UTR with poly A signal AGTAA. It is well known 
that the conserved AATAAA site regulates gene trans-
cription. The removal of this sequence prevents synthesis 
of mRNA from the transcription unit. Mutation within the 
AATAAA causes abnormal mRNA formation (Higgs et al., 




HUMAN PRLR HETEROGENEITY CONSTITUTES A 
REGULATORY SYSTEM 
 
Multiple forms of human PRLR were reported in a variety 
of human tissues (Boutin et al.,1989; Kline et al., 1999; 
Kline et al., 2002; Hu et al., 2001; Trott et al., 2003; Fuh 
and Wells, 1995; Somers et al., 1994; Laud  et al., 2000; 
Peirce and Chen, 2001; Leav et al., 1999; Nevalainen et 
al., 1997; Ling et al., 2003; Otte et al., 2002) (Figures 2 
and 3). They might result from either alternative splicing 
or proteolysis. The differential forms of PRLR might in-
volve in different PRL signaling pathway and contribute to 
the distinct functionalities of PRL. Here, we illustrated the 





Long form of PRLR, a member of the cytokine receptor 
superfamily, was cloned from hepatoma (Hep G2) and 
breast cancer (T47D) libraries by using a rat PRL 
receptor cDNA probe (Davis and Linzer, 1989). The 
receptor contains an extracellular domain, a trans-
membrane domain and an intracellular domain. The ECD 
is composed of the cytokine receptor homology region, 
which contains two domains, referred to as S1 and S2. 
The ECD shows the analogies with the type III 
fibronectin-like domains (see Figure 4). The type III 
fibronectin domains involve the activation of focal 
adhension kinase (FAK), Rho and Rac (Skiyama, 1996). 
The S1 domain contains most of ligand binding sites, the 
S2 domain contains conserved motif WSXWS across the 
cytokine receptor superfamily (Lee et al., 2006). The TM 
containing 24 amino acids is rarely studied. The PRLR 
anchorages on cell membrane via some hydrophobic 
amino acids and works with ICD and TM might regulate 
internalization   (Gadd  and  Clevenger,  2006).  The  ICD  






Figure 3. A sequence alignment comparison of multiple PRLR “___” indicates truncated or deletion parts of PRLR. Blackened “Y” 
stands for sites for tyrosine phosphorylation. Highlighted boxes indicate WSAWS, Transmembrane, Box1 or Box2 domains as indicated.  






Figure 4. Sequence comparison of PRLR extracellular domain with type III fibronectin domains. 
The ECD shows the analogies with the type III fibronectin-like domains (FN3A, FN3B). The type III 
fibronectin domains involve the activation of focal adhension kinase (FAK), indicating a link of 




contains conserved box 1, box 2 and multiple tyrosine 
activation sites in the cytokine receptor super family 
(Bole-Feysot et al., 1998). Box 1 was recognized 
necessary for activating Janus kinase 2 (Jak2) (Bole-
Feysot et al., 1998). The function of box 2 is largely un-
clear. In rodent studies, the most C-terminal tyrosine resi-
dues were dedicated to the activation of signal transducer 
and activator of transcription 5 (Stat5) and SH2-con-
taining protein tyrosine phosphatase (SHP2) (Lee et al., 
2006). The different box of ICD might contribute to activa-
tion of different signal molecules involved in MAP kinase, 






The  intermediate  PRLR  was  found  first  in  T47D  cells  
(Kline et al., 1999). It is a truncated isoform resulting from 
a partial deletion of exon 10 and frame shift in protein 
encoding. The isoform generates a novel 13 amino acid 
sequence. It has been demonstrated to activate Jak2 in 
response to PRL, but not to activate the Fyn tyrosine 
kinase. In addition, the different levels of transcription 
were revealed in different tissues (Teilum et al., 2005). 
Hence, intermediate PRLR may work in different signa-





The  S1 was characterized in T47D cells (Davis and 
Linzer, 1989). The receptor was generated from alter-
native splicing to remove exon 4 and 5 in coding region. 
The  S1 was named for entire loss of S1 domain in ECD. 
A 24 amino acid signal peptide encoded by partial exon 3  




was cleaved by proteolysis. The affinity of the  S1 for 
ligand is reduced 7 fold versus long PRLR by radioligand 
binding analysis. However,  S1 regulates intergrin-
associated signaling cascades.  S1 also activates Jak2 
in transfected cells in response to ligand. These indicate 
that without S1 domain, S2 domain also binds to ligand 
and lead to signal transduction in response to ligand 
stimulation (Kline et al., 2002). However, due to loss of 
S1 domain, ligand binding might regulate receptor confir-
mation differently from long PRLR and further, trigger 





The short form S1a actually is longer than the inter-
mediate form PRLR (Hu et al., 2001; Trott et al., 2003). 
This receptor has the domains translated from exon 3 all 
the way down to exon 11. Partial exon 10 and partial 
exon 11 were alternatively spliced to produce a pre-
mature mRNA with frame shift in protein sequence. 
Therefore, it in effect produces a mutant protein with box 
1 and box 2. The S1a was found in both normal and 
breast cancer tissues. More, its binding affinity to ligand 
is equivalent to that in long form PRLR (Hu et al., 2001). 
Albeit S1a possesses Jak2 and Stat5 contact sites, box 1 
and box 2 and activates Jak2, it does not induce beta-
casein luciferase expression in response to PRL in 
HEK293 cells (Hu et al., 2001). A tyrosine residue at or 
near 382 might be necessary for PRL induced gene 
transcription (Trott et al., 2003). The S1a contains two 
tyrosine residues downstream from box 2 at position 





This receptor has the region encoded from exon 3 to 
exon 9 and partial exon ll coding region. Alternative 
splicing from exon 9 to exon 11 produced a frameshit in 
protein coding. The S1b structurally has a box 1 but no 
box 2. The S1b also was regarded as a dominant nega-
tive form of PRLR in terms of beta-casein promoter 
luciferase assay in response to PRL. Similar to S1a, the 
S1b was detected in samples of human breast, placenta, 
kidney, liver and pancreas (Trott et al., 2003). The S1b 
has 3-fold higher specific binding to hGH than the long 





The receptor was regarded as an encoded protein with-
out signal peptide and exon 4-translated region. This 
coded protein was assumed to be a nuclear receptor. 
Similar to  4- 7/11, it has no evidence showing that it 





box2 and its function remains unknown. It is likely that it 






The receptor has a deletion in the exons 8, 9, and 10 
coding regions. Alternative splicing leads to a frame shift 
in the junction between exon 7 and exon 11. Thus, it was 
demonstrated to be a secreted soluble PRL-binding 
protein. The  7/11 lacks box 1 and box 2 sites for Jak2 
and Stat5 activation (Trott et al., 2003). Differential level 
of  7/11 expression was determined in normal breast, 
colon, placenta, kidney, liver, ovary, pancreas, breast and 





Compared with  7/11 PRLR, the 4- 7/11has an 
additional deletion for entire exon 3 and exon 4 translated 
region. It is uncertain whether or not it is a product of  
7/11 PRLR proteolysis (Trott et al., 2003), especially its 
first amino acid is methionine. Because it does not lack a 
24 amino acids signal peptide, it is also a secreted 
soluble protein. Now no evidence shows that it does not 
bind to ligand. Similar to the  S1 PRLR, this receptor 
also has S2 domain for PRL binding. It is possible that 
this receptor binds to PRL. Similar to  4-SF1b, little is 
reported about 4- 7/11 protein information. Although 
their deduced sequences were reported, it is possible 





This is a deduced protein from isolated mRNA sequence 
in human breast cancer cell line BT-474. Putatively, it is a 
soluble protein for that it lacks transmembrane domain 
and has no longer intracellular domain from exon 8. How-
ever, it has a S2 binding site and two extra amino acids 
AW, which comes form alternative splicing by exon 7 and 
exon 9 (Fuh and Wells, 1995). Theoretically, it does not 
contact downstream signal. The short PRLR might 





SS2 is so far discovered the shortest PRLR with only 
partial ECD in T47D and MCF7 cells. The form has a 170 
bp deletion generated by alternative exon 6 splicing in 
PRLR transcripts. The deletion induced a frame shift in 
protein coding. The protein may be a secreted isoform of 
PRLR. Due to loss of WSXWS domain, the protein might 





is higher in tumoral tissues than normal tissues. This sug-
gests that SS2 mRNA or protein might down-regulate 
long PRLR mRNA/protein (Laud et al., 2000). Hence, 
short PRLR mRNA formation might be a regulatory sys-
tem by blocking the formation of long PRLR mRNA. 
 
 
HUMAN SHORT FORMS OF PRLR IS NOT THE 
DOMINANT NEGATIVE  
 
Human and rodent short forms of PRLR were regarded 
as the dominant negative forms in transfected cells. Due 
to the lack of box 2 and downstream tyrosine phos-
phorylated sites, some short PRLRs, such as S1a and 
S1b, did not induce beta-casein luciferase expression in 
some cell types. In other words, they are not able to 
activate Stat5. However, short forms of PRLR, such as 
S1 might work by the Jak2-Stat5 pathway. Additionally, 
albeit neither S1a nor S1b did not trigger the Jak2 –Stat5 
pathway, we recently discovered that S1b dedicated to 
the inhibition of cancer cell growth (Clevenger et al., 
1992). Structurally, both S1a and S1b have box1 site, 
which is necessary for Jak2 and MAPK activation. The 
Stat5 activation needs box 2 and downstream phosho-
rylated tyrosine site. The short PRLR might have prolife-
rative and differentiative function depending on cell types 
and physiological condition (Das and Vonderhaar, 1995; 
Halperin et al., 2008; Wu et al., 2005). In normal cells, the 
formation of short forms of PRLR might be a regulatory 
system to repress long PRLR. In tumor cells, the short 
PRLR might downregulate long form signaling by hetero-
dimerization (Qazi et al., 2006). It is conceivable that the 
long PRLR is related to proliferation whereas the short 
PRLR is relevant to differentiation (Wu et al., 2003). 
Therefore, alternative splicing is a means to regulate the 
ratio of long and short PRLR to ensure appropriate PRLR 
physiological functions (Meng et al., 2004). 
 
 
GENES COLOCALIZED ON CHROMOSOME 5 MIGHT 
INTERPLAY 
  
Gene localization analysis on chromosome 5 via NCBI 
blast shows that human PRLR gene was closely linked to 
growth hormone receptor gene (5p13-p12) and inter-
leukin 7 receptor (5p13) gene and co-localized with the 
genes which express Fyn binding protein (5p13.1), leu-
kemia inhibitory factor receptor (5p13-p12), cyclin B1 
(5q12), interferon regulatory factor 1 (5q31.1), interleukin 
3,4, 5, 9 (5q31), interleukin 12 B, IL13 (5q31-5q31), 
IL17B (5q32-5q34) (5q31.3-q33.1), interleukin 6 receptor 
signal transducing subunit gp130 ( 5q11), colony stimu-
lating factor 1 receptor (5q33), colony stimulating factor 2 
receptor (5q31), glucocorticoid receptor (5q31-q32), 
dopamine receptor D1A, fibroblast growth factor 1 
(5q31.3-q33.2), fibroblast growth factor 4 (5q35), fibro-
blast growth  factor  10  ( 5p13-5p12 ),  fibroblast  growth  




factor 18 ( 5q34-5q35.1), VEGF3 (5q34-5q35 ), adren-
ergic alpha 1 B receptor ( 5q23-q32), adrenergic alpha 1 
A receptor ( 5q32-q34), gamma-aminobutyric acid (GABA) 
A receptor alpha 1 and alpha 2 (5q34-q35), GABA beta 2 
(5q34-5q35 ), GABA gamma 2 (5q31.1-5q33.1), mitogen-
activated protein kinase kinase kinase 1 (MAP3K1) 
(5q11.2), mitogen-activated protein kinase 9 (5q35), etc. 
Most products of those genes belong to cytokine superf-
amily class I, which shares the conserved WSXWS (Trp-
Ser-X-Trp-Ser) domain (Bole-Feysot et al., 1998). PRLR 
and GHR have strong similarity in structure. Alternative 
splicing produced multiple 5’-UTR, some deleted coding 
regions and 3’UTR in GH (Hu et al., 2002). More, human 
GH binds PRLR, indicating that they use the same 
signaling pathways and may share the similar features. It 
was demonstrated that soluble truncated growth hormone 
receptor (GHR) lacking the intracellular domain inhibits 
the function of LF GHR. This happened probably by the 
formation of nonproductive dimers or competition of 
ligands (Hu et al., 2002). PRLR might involve immuno-
regulation by interacting with IL-7 receptor, LIF receptor, 
IRF-1, some interleukins (3, 4, 5, 9, 12B, 13, 17B), gp130 
CSF1, cyclin B1, etc. PRL has been shown to increase 
IL-2 receptor and inhibit apoptosis of lymphocytes in rats 
(Mukherjee et al., 1990; LaVoie and Witorsch, 1995) and 
PRL increased IRF-1 transcription (Yu-Lee et al., 1990). 
In the murine T-helper L2 cells, PRL alone induces the 
expression of IRF-1 but requires co-incubation with IL-2 
for inducing cyclin B1 (Clevenger et al., 1992). PRL 
induces activation of kinase Fyn by activating PRLR (Ali 
and Ali, 2000). It is well known that PRL activates MAPK 
pathway via binding PRLR (Clevenger et al., 1994). PRL-
PRLR interaction might involve angiogenesis. The prote-
olytic fragments of native PRL inhibits angiogenesis, 
whereas intact human PRL has angiogenic activities (Lee 
et al., 2007), which might be related to the interaction bet-
ween PRLR and fibroblast growth factors, VEGF. GABA 
and dopamine inhibit PRL secretion from pituitary 
(Matsushita et al., 1983). Prolactin and glucocorticoids 
act in concert to stimulate transcription factors respon-
sible for hormone-dependent milk protein gene expres-
sion (Cella et al., 1998). Interaction among the genes, 
which are localized on the same chromosome, was 
reported. For example, GR and beta-2 adrenergic recep-
tor genes in close proximity on chromosome 5, which 
have similar evolutionary features and perhaps functional 
interaction (Ukkola et al., 2001). GR and ADR genes 
were shown to be responsible for obesity and fat distri-
bution phenotypes (Ukkola et al., 2001). Gene-gene 
biological interaction refers to the co-participation of two 
factors in the same causal mechanism (Yang et al., 1999). 
The probability of correlations (linkage disequilibrium) 
between two genes on the same chromosome will 
increase, especially for those that are physically close to 
each other (Yang et al., 1999). Thus, PRLR-linked genes 
on chromosome 5 might interact to keep the stability in 
heredity and be convenient for mutual modulation. 




Table 1. Feature comparisons in prolactin receptors. 
 







LF 622 - +/- +/+ +/+ - 
IF 349 + +/- +/+ +/+ - 
∆S1 521 - +/+ +/+ +/+ - 
S1a 376 + +/- +/+ N/D - 
S1b 288 + +/- +/- N/D - 
∆4-SF1b 217 + +/+ +/- N/D + 
∆7/11 268 + + -/- -/- + 
∆4-∆7/11 197 + +/+ -/- -/- + 
SS1 206 + +/- -/- -/- + 




CONCLUSIONS AND PERSPECTIVE  
 
Multiple structures of the PRLR transcripts and protein 
reflect the requirements for PRL-regulated function. Here-
by, we just reviewed the structure and function and signa-
ling pathways of some cloned and a few putative PRLRs 
(see Table 1). In fact, the number of prolactin and their 
transcripts is far more than we herein described. These 
mRNAs were obtained from a limited number of probes. It 
is believed that more and more human PRLR forms will 
be discovered including those, which might result from 
totally different genes. Tissue-specific promoter in PRLR 
transcripts will be unveiled. Some PRLR features and 
functionalities will be further characterized. It has been 
noted that in PRL triggered response, the influence of 
growth hormone should not be ignored since growth hor-
mone also binds PRLR. Some short form of PRLR trans-
cripts and protein might play a role in tumor inhibition and 
differentiation. In summary, short PRLR RNA might 
regulate the number and structure of long PRLR RNA via 
heterodimization or RNAi. Additionally, short PRLR 
protein might regulate long PRLR or other cytokine 
receptor superfamily member by forming ‘homology zip-
per’ which can open or close so as to be suitable for the 
requirement of cell function. Based upon homo-and 
heter-dimizeriztion of PRLR, soluble PRLR can be 
modified to link to a drug for target leukemia or vascular 
diseases. We demonstrated that S179D PRL upregulates 
the short PRLR in mouse HC11 cells. Meanwhile, in 
human short PRLR transfected HEK293 cells, S179D 
PRL induced AP-1 luciferase expression. Human short 
forms of PRLR is not the dominant negative, it might use 
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